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Abstract: Eosinophils are the principal effector cells for allergic 
inflammation in a variety of diseases, in which they contribute to tissue 
damage and remodelling processes via the secretion of cytotoxic granular 
proteins and cytokines. The intracellular mechanisms that control the 
activation, recruitment and survival of eosinophils are fundamental in 
understanding these disease processes. Phosphoinositide 3-kinase (PI3K) 
has been shown previously to be essential for eosinophil chemotactic 
responses to some stimuli but not others. Human blood neutrophils have 
been shown to utilize two antagonistic signalling pathways for chemotaxis: 
PI3K and p38 mitogen-activated protein kinase (p38 MAPK). In the present 
study, the role of p38 MAPK in chemotactic responses of an eosinophil-
differentiated myeloid leukaemia cell line (EOL-1) and human peripheral 
blood eosinophils to a range of stimuli - platelet-activating factor (PAF), 
eotaxin 1 (CCL11), RANTES (CCL5), interleukin 8 (IL8, CXCL8) and 
IL16 - was explored through the use of the p38 MAPK α/β isoform 
inhibitor, SB 203580. SB 203580 caused significant inhibition of 
chemotactic responses of both EOL-1 cells and blood eosinophils to 
eotaxin 1 and RANTES (≥75% inhibition at 1 µM SB 203580, p<0.01) 
but had no effect on the migration induced by PAF and IL16 (<25%) and 
little or no effect on responses to IL8. Responses to PAF - but not 
eotaxin - have been shown previously to be suppressed by PI3K 
inhibition. The complementary pattern of inhibition observed in the 
present study provides evidence that distinct PI3K-dependent and p38 
MAPK-dependent chemoattractants may also exist for eosinophils.  
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Introduction  
Eosinophils are initiator and effector cells of Th2-
mediated immunity (Ravin and Loy, 2016). They are 
associated with key components of inflammation in a 
variety of chronic diseases affecting the airways (Eng and 
DeFelice, 2016), heart (Séguéla et al., 2015) and 
gastrointestinal system (Hogan et al., 2013). Eosinophils 
are characterized by secretory granules that contain 
multiple cytotoxic proteins (Ravin and Loy, 2016). 
Additionally, eosinophils produce reactive oxygen 
metabolites, lipid mediators and cytokines, all of which 
are capable of causing severe host tissue damage in 
eosinophilic inflammation (Barnes, 2011). 
Eosinophil migration appears to be modulated by two 
fundamental processes: Cell adhesion systems located at 
the site of inflammation in local endothelium and 
epithelium and chemotactic signals elicited through 
cytokine, chemokine and other chemoattractant receptors 
(Lampinen et al., 2004). A range of inflammatory 
mediators and cytokines have been identified as 
eosinophil attractants and activators, including platelet-
activating factor, CC chemokines including eotaxin 
(CCL11) (Mishra et al., 2005) and regulated on activation 
normal T-cell expressed and secreted (RANTES, CCL5) 
(Svensson et al., 2009), CXC chemokines including 
interleukin 8 (IL8, CXCL8) (Bates et al., 2010) and the 
lymphocyte chemoattractant factor interleukin 16 (IL16) 




(Rand et al., 1991). The cellular signalling pathways 
responsible for evoking and regulating eosinophil 
chemotaxis toward these chemoattractants are 
incompletely understood, although a role for receptor-
mediated activation of phosphoinositide 3-kinase (PI3K) 
in responses to certain stimuli has been identified 
(Mishra et al., 2005). 
The p38 MAP kinase (MAPK) signalling pathway 
plays an important role in inflammation and other 
physiological processes. Specific inhibitors of p38 
MAPK α and β block production of the major 
inflammatory cytokines (e.g. tumour necrosis factor α and 
interleukin 1) and other proteins (e.g. cyclooxygenase 2) 
and are anti-inflammatory in animal models of disease 
(Ono and Han, 2000). A major function of the pathway is 
post-transcriptional control of inflammatory gene 
expression. Inhibitors of p38 MAPK have been shown 
to reduce inflammatory cytokine production and 
eosinophil infiltration into the lungs in animal models 
of asthma (Underwood et al., 2000) and to inhibit 
angiogenesis in a murine model of rheumatoid 
arthritis (Jackson et al., 1998).  
SB203580 is a selective inhibitor of the α and β 
isoforms of p38 MAPK that inhibits the cytokine-
induced adhesion, shape change and transmigration of 
eosinophils (Ip et al., 2003), as well as inhibiting 
eotaxin 1 production in human primary lung fibroblasts 
(Rokudai et al., 2006) and capsaicin-induced production 
of PAF in oesophageal epithelial cells (Ma et al., 2010). 
Pharmacological inhibition of receptors and signal 
transduction molecules in human eosinophils has shown 
that the release of oxygen free radicals in response to 
eotaxin 1 is relatively more dependent on the p38 MAPK 
pathway than the response to bacterial formyl peptide 
chemoattractants (Svensson et al., 2009).  
Studies in human neutrophils revealed a signalling 
hierarchy for chemoattractants in which responses to 
specific attractants exhibited a dependence upon either 
PI3K or p38 MAPK (Heit et al., 2007). Since we have 
shown previously that eosinophil responses to certain 
attractants are dependent upon PI3K while others are not 
(Mishra et al., 2005; Hasan et al., 2010), we undertook a 
study to determine whether eosinophil chemotactic 
responses to a number of factors-including those known 
to be PI3K-independent-involved p38 MAPK.  
Materials and Methods 
Cells 
The human leukaemia cell line, EoL-1 was 
cultured and differentiated to an eosinophilic 
phenotype as described previously (Al-Rabia et al., 
2004). Cell viability was determined every 2 days by 
trypan blue dye exclusion. Viability was maintained at 
>90% throughout cultures. 
Human peripheral blood eosinophils were isolated 
from non-asthmatic volunteers as described previously 
(Dent et al., 1998). Blood donors gave informed consent 
to the use of their cells and the project was approved by 
the North Staffordshire Local Research Ethics 
Committee (reference 06/Q2604/15).  
Chemotaxis Assay  
Chemotactic responses of differentiated EoL-1 cells 
and human peripheral blood eosinophils were measured in 
a 96-well blind chamber assay using 5 µm pore-size 
filters, as described previously (Mishra et al., 2005).  
Statistical Analysis 
Data are expressed as arithmetic mean ± standard 
error of the mean (SEM) from the indicated numbers 
of experiments. Statistical analyses were performed 
using SPSS version 21 for PC (IBM Corp., Armonk 
NY, USA). For comparisons of multiple groups 
(i.e. varying concentrations of SB 203580), repeated-
measures analysis of variance (ANOVA) was 
followed by post hoc pairwise comparisons with 
untreated (control) cells using Dunnett’s test for 
multiple comparisons. A probability (P)<0.05 was 
defined as significant throughout.  
Results  
Effect of α/β p38 MAPK Inhibitor (SB 203580) 
on Chemotactic Responses of EOL-1 Cells and 
Human Peripheral Blood Eosinophils to Eotaxin 
1 and PAF  
Eosinophil-differentiated EoL-1 cells exhibited 
chemotactic responses to both PAF and eotaxin 1, with 
optimal concentrations of 100 nM and 30 nM, 
respectively (Dent et al., 1998). Chemotactic responses 
to eotaxin 1 were inhibited in a concentration-
dependent manner by SB 203580. In contrast, 
inhibition of PAF-induced chemotactic responses by 
SB 203580 did not achieve statistical significance at 
concentrations up to 10 µM (Fig. 1A).  
Both PAF and eotaxin 1 stimulated migration of 
human peripheral blood eosinophils, with optimal 
concentrations of 30 nM for each stimulus (Dent et al., 
1998). The response to eotaxin was inhibited 
concentration-dependently by SB 203580, while the drug 
had no significant effect on the response to PAF at 
concentrations of 100 µM (Fig. 1B).  
Effect of SB 203580 on Chemotactic Responses of 
EOL-1 Cells to IL8, IL16 and RANTES  
In preliminary experiments, the optimal 
concentration of IL8 for induction of both 




differentiated EOL-1 cell and blood eosinophil 
chemotaxis was found to be 10 nM, while that for 
RANTES and IL16 was 0.1 nM (Hasan, 2008). 
Chemotactic responses to RANTES were inhibited by 
SB 203580 in a concentration-dependent manner 
(Fig. 2A). SB 203580 had no significant effect on 
chemotactic responses to IL16 or IL8 at concent-
rations up to 10 µM (Fig. 2B and 2C).  
Effect of SB 203580 on Chemotactic Responses of 
Human Peripheral Blood Eosinophils to IL8, IL16 
and RANTES  
SB203580 inhibited the chemotactic response of 
human peripheral blood eosinophils to RANTES in a 
concentration-dependent manner (Fig 3A). SB 203580 
had no significant effect on chemotactic responses to 
IL16 or IL8 at concentrations up to 10 µM (Fig 3B & C).  
 
     
 
Fig. 1. Effects of SB 203580 on (A) eosinophil cell line EoL-1 and (B) human peripheral blood eosinophil chemotactic responses to 
100 nM PAF (●) and 30 nM eotaxin 1 (●). Data are shown as mean ± SEM from six experiments conducted in triplicate for 
each inhibitor combination. *p<0.05, **p<0.01 compared with control response in the absence of inhibitor by repeated-






Fig. 2. Effects of SB 203580 on EoL-1 cell chemotactic responses to (A) 0.1 nM RANTES, (B) 0.1 nM IL16 and (C) 10 nM IL8. 
Data are shown as mean ± SEM from four experiments conducted in triplicate for each inhibitor combination. *p<0.05, 
**p<0.01 compared with control response in the absence of inhibitor 








Fig. 3. Effects of SB 203580 on blood eosinophil chemotactic responses to (A) 0.1 nM RANTES, (B) 0.1 nM IL16 and (C) 10 nM 
IL8. Data are shown as mean ± SEM from four experiments conducted in triplicate for each inhibitor combination. **p<0.01 
compared with control response in the absence of inhibitor 
 
Discussion  
Previous studies have shown a differential 
dependence of chemotactic responses in human 
eosinophils and eosinophil-differentiated EOL-1 cells 
upon PI3K. Responses to the phospholipid 
inflammatory mediator platelet-activating factor (PAF) 
are highly sensitive to suppression by PI3K inhibitors 
(Mishra et al., 2005), with the PI3Kγ isoform 
specifically essential to these responses (Hasan et al., 
2010). In contrast, responses to the CC chemokine 
eotaxin 1 - a key eosinophil chemoattractant in airway 
secretions in severe asthma (Dent et al., 2004) - are 
unaffected by PI3K inhibitors (Mishra et al., 2005; 
Hasan et al., 2010). It is, therefore, apparent that 
chemotactic responses of eosinophils are not mediated 
by a single intracellular signalling pathway.  
In a landmark study Heit et al. (2002) demonstrated 
the existence of a signalling hierarchy that allows 
neutrophils to migrate towards higher concentrations of 
specific chemoattractants against concentration gradients 
of other attractants. Heit et al. (2002) classified these two 
types of substance as intermediary chemoattractants (e.g. 
IL8 and leukotriene B4), with actions mediated by PI3K 
and end-stage chemoattractants (e.g. complement 
anaphylotoxin C5a and bacterial formyl peptide fMet-
Leu-Phe) whose actions are mediated by p38 MAPK.  
In the present study, chemotactic responses of 
eosinophils to a range of stimuli were assessed to 
determine their sensitivity to an inhibitor of the α/β 
isoforms of p38 MAPK, SB 203580.  
In a complementary finding to that of our previous 
reports (Mishra et al., 2005; Hasan et al., 2010), we 
found that responses to eotaxin 1 were highly sensitive 
to inhibition by SB 203580 while those to PAF were 
not. Among the other stimuli studied, another CC 
chemokine - RANTES - also exhibited chemotactic 
responses sensitive to p38 MAPK inhibition. While 
both of these chemokines are able to exert actions 
through multiple receptors, they have a single common 
target expressed in eosinophils: the CCR3 receptor 
(Elsner et al., 2004). This may account for the shared 
dependence of responses to these two stimuli upon the 
same signalling pathway.  
Eotaxin may stimulate chemotaxis through activation 
of one or more protein kinases, which then activate 
effector molecules that recruit p38 MAPK. These in turn 
activate downstream molecules which induce 




polarization and cytoskeletal reorganization. Thus, 
eotaxin and RANTES may induce the chemotaxis of 
eosinophils by a p38 MAPK-dependent mechanism. The 
results of the present study are similar to those reported 
by Stubbs et al in 2002, which showed evidence of 
involvement of p38 MAPK in multiple eosinophil 
responses to eotaxin (Stubbs et al., 2002).  
While the CXC chemokine IL8 is recognized as 
having chemoattractant activity for eosinophils, the 
signalling pathways involved in this response are poorly 
understood. IL8 activates MAP kinases 3 and 1 (ERK1 
and ERK2) in IL5-primed eosinophils and this action is 
necessary for the induction of leukotriene C4 synthesis 
(Bates et al., 2000), however the signal transduction 
events involved in chemotaxis have not been identified. 
Although IL8 was classified as an intermediate (PI3K-
dependent) attractant for neutrophils (Heit et al., 2002), 
the receptor presumed to mediate this response in 
neutrophils - CXCR1 - has not been shown to be 
expressed by eosinophils (Liu et al., 2003). We 
demonstrate here that IL8-induced eosinophil 
chemotaxis does not exhibit the same degree of 
dependence upon p38 MAPK as the CCR3 agonists 
eotaxin 1 and RANTES, with only marginal levels of 
inhibition (up to approximately 25%) observed in the 
presence of SB 203580 at concentrations that produce 
approximately 75% inhibition of responses to the CC 
chemokines. It remains to be determined which other 
signalling pathways-possibly including PI3K-dependent 
mechanisms-contribute to CXC chemokine chemotaxis 
responses in eosinophils. 
The lymphocyte chemoattractant factor, IL16, 
induces activation and suppressor events in T 
lymphocytes through a variety of mechanisms involving 
multiple receptors (Lynch et al., 2003). While CD4 is the 
key receptor for IL16 actions on T lymphocytes, non-
lymphoid immune effector cells may utilize other 
receptors for this cytokine and a role for PI3K in 
chemotactic responses to IL16 in mast cells has been 
demonstrated (Qi et al., 2006). In the present study there 
was no apparent dependence upon p38 MAPK of 
eosinophil chemotactic responses to IL16, with no 
inhibition of responses observed at any concentration of 
SB 203580. While this cannot be taken as evidence of 
involvement of another specific signalling pathway, it 
does contribute to an overall picture of stimuli shown 
elsewhere to evoke PI3K-dependent responses exhibiting 
no dependence upon p38 MAPK in our studies.  
Future research studies should focus on stimulus, 
response and cell-type heterogeneity of p38 MAPK 
dependence. The present study has utilized a single 
inhibitor of the α/β isoforms of the enzyme. Further 
studies are required to investigate the functions of the 
individual isoforms α, β, δ and γ of p38 MAPK and the 
mechanisms by which they contribute to activation of 
human eosinophils. The interference or cross-talk of this 
pathway (p38 MAPK pathway) with the other pathways 
that influence the migration and accumulation of human 
eosinophils will be an interesting field for future studies.  
Conclusion 
Chemotactic responses of human eosinophils to CC 
chemokines (eotaxin 1 and RANTES) are dependent upon 
α/β p38 MAPK. Responses to PAF and IL16 are not 
dependent on α/β p38 MAPK, while responses to a CXC 
chemokine (IL8) show partial dependence. The 
dependence of responses of PAF and eotaxin 1 on α/β p38 
MAPK are a mirror image of the dependence of these 
responses on PI3K, suggesting that different classes of 
chemoattractants utilizing different intracellular signaling 
pathways may exist for eosinophils, as has been described 
for human neutrophils. 
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